Enveric Biosciences is a biotechnology company based in Naples, FL, dedicated to developing innovative neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. With their unique discovery and development platform, The Psybrary, Enveric has built a strong Intellectual Property portfolio of New Chemical Entities targeting specific mental health indications.
Enveric Biosciences is focused on advancing novel neuroplastogen therapeutics that have the potential to benefit millions of patients worldwide. Their development pipeline includes the EVM301 series, with lead drug candidate EB-003, aimed at addressing anxiety, depression, and other disorders through a prescription model. With a commitment to innovation in the field of CNS, Enveric is poised to make significant contributions to the advancement of mental health treatments.
Generated from the website